Lundbeck profits drop on new-launch spending; Endo boosts sales, hikes forecast; FDA expands Chinese inspection force;

@FiercePharma: ICYMI: PATH Malaria Vaccines Initiative nets $156 million from Gates Foundation. FierceVaccines story | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Here's a first: Regeneron cuts forecast after hard-charging Eylea sales miss. Article | Follow @CarlyHFierce

> Denmark's Lundbeck saw profits decline as generics erode sales of older meds and the company plows money into new product launches. Report

> Endo International ($ENDP) posted a 16% revenue hike for the third quarter, thanks in part to new acquisitions, and raised its earnings forecast for the year. Release

> The FDA is boosting the size of its China office, adding new inspectors to check out food and drugs destined for the U.S. market. Report

> The FDA slapped new warnings about antibiotic-associated diarrhea and drug interactions onto a class of stomach drugs known as proton pump inhibitors, three years after an advocacy group started lobbying for the change. Report

> Ironwood Pharmaceuticals ($IRWD) said its new gastrointestinal drug Linzess saw prescriptions grow by 22% for the third quarter. Release

> Merck KGaA's pharma CEO Stefan Oschmann was elected to serve as president of the International Federation of Pharmaceutical Manufacturers and Associations, replacing Eli Lilly ($LLY) chief John Lechleiter. Release

> Actavis CFO R. Todd Joyce will retire early next year, but will stay in his post until the company finds his replacement. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Spinoff Halyard Health gets boost from Ebola fears, stock up modestly in market debut. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Maryland provides seed financing to 15 med tech startups. Item | Follow @VarunSaxena2

@EmilyWFierce: This just in from the $ACT earnings call: "Actergan." | Follow @EmilyWFierce

> Former Boston Scientific engineer charged with intellectual theft. More

> Cantel Medical buys Italian healthcare manufacturer for $24.5M. News

Biotech News

@FierceBiotech: Novartis gears up for FDA scrutiny with a new blood cancer drug. Report | Follow @FierceBiotech

@JohnCFierce: Should Chris Viehbacher replace John Lechleiter at $LLY? Now that would be interesting. | Follow @JohnCFierce

@DamianFierce: The most metal researcher in all of science. More | Follow @DamianFierce

@EmilyMFierce: Science Cafés are growing in popularity. More | Follow @EmilyMFierce

> GlaxoSmithKline heads to the FDA with its next big respiratory bet. Report

> AstraZeneca's $2B oncology contender shows promise in prostate cancer. Article

> Can Rockwell Medical win FDA approval for its dialysis drug? More

Drug Delivery News

> Distinct, compartmental reactions in an 'artificial cell' offer controlled delivery action. More

> OptiNose submits NDA to FDA. Item

> MIT spinoff SQZ Biotech nabs startup prizes for cell-squeezing delivery enhancer. Story

> AstraZeneca, University of Manchester create new center for advanced drug delivery. Article

> Study: Timing of administration an oft-overlooked factor in drug delivery. More

Diagnostics News

> Diagnostics companies homing in on rapid mobile tests to quell Ebola outbreak. Report

> Myriad signs expanded deal with AbbVie for cancer Dx. More

> AstraZeneca shells out $150M for cancer Dx outfit Definiens. Item

> LabCorp bets $6B in diversification deal with Covance. Story

> Qiagen beats the Street's Q3 numbers with success of companion Dx and next-gen TB test. Article

Pharma Marketing News

> Who's king of the orphan drug hill? BMS, Merck, Celgene and Roche, to name a few. Article

> A tale of two studies: Prescribe Pradaxa 'with caution'? Or rely on FDA's safety backing? More

> Sovaldi's not the only superhero launch: Meet the rest of the pharma Avengers. Story

> Sales speedster Eylea faces a tougher track in new DME market, Regeneron SVP says. Article

And Finally ... With a year of tough endurance training, sedentary folks can achieve the heart benefits accorded to elite athletes. Report (sub. req.)

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.